{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.0', 'Investigational Plan', '5.1', 'Overall Study Design and Plan: Description', 'The study is designed to enroll approximately 740 SCLC subjects to obtain approximately', '480 subjects with DLL3 high expression in tumor (DLL3high) and to meet scientific and', 'regulatory objectives without enrolling an undue number of subjects in alignment with', 'ethical considerations. DLL3high is defined as > 75% tumor cells staining positive', 'according to the VENTANA DLL3 (SP347) IHC Assay.', 'This is a Phase 3, randomized, double-blinded, placebo-controlled, multinational, and', 'multicenter study. Approximately 300 clinical sites will participate.', 'Eligible subjects will be randomly assigned in a 1:1 ratio to receive 0.3 mg/kg', 'rovalpituzumab tesirine or placebo, and will receive their assigned therapy on Day 1 of', 'each 6-week cycle, omitting every third cycle. Subjects will also receive 8 mg orally (PO)', 'of dexamethasone or placebo twice daily on Day -1, Day 1 (the day of dosing), and Day 2', 'of each 6-week cycle, omitting every third cycle. Subjects will be stratified by', 'RECIST v1.1 response after completion of first-line platinum-based chemotherapy at', 'screening assessment (SD VS. PR/CR), DLL3 expression (Unknown VS. 0% to < 25% VS.', '25% to < 75% VS. 75% or above), history of central nervous system (CNS) metastases', '(Yes VS. No), and for subjects with no history of CNS metastases, PCI VS. no PCI.', 'Survival Follow-up will continue until the endpoint of death, the subject becomes lost to', 'follow-up or withdraws consent, or termination of the study by AbbVie, whichever occurs', 'first.', 'A schematic of the study is provided in Figure 1, Study Schema.', '32']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Figure 1.', 'Study Schema', 'VV', '...', 'R', 'rovalpituzumab', 'Clinical Benefit', 'A', 'tesirine/dexamethasone', '(SD, PR, CR)', 'N', 'q6 wk (omit every 3rd cycle)', 'S', 'First-line', 'D', 'No', 'Screening', 'D', 'PTFU', 'os', 'C', 'o', 'End of', 'Progression', 'Chemotherapy', 'PCI\u00b9', 'Procedures', 'A', 'L', '& Labs\u00b2', 'M', 'Treatment', '(4 Cycles)', 'Y', 'I', 'C', '1', 'os', 'Z', 'Progression', 'E', '...', '3', 'placebo q6 wk', '(omit every 3rd cycle)', 'Arrowheads = blinded investigational product administration; CR = complete response; os = overall survival;', 'PR = partial response; PTFU = post-treatment follow-up; SD = stable disease', '1. Upon completion of first-line platinum-based chemotherapy, eligible subjects must be offered prophylactic cranial', 'irradiation (PCI), if offering this procedure is not contradictory to country or institutional guidelines. Subjects', 'receiving PCI must complete it prior to randomization into the study.', '2.', 'Collection of tumor material for DLL3 testing will be provided any time after the signing of the informed consent', 'and prior to randomization.', '3.', 'Subject is eligible to be randomized at least 3 but no more than 9 weeks from Day 1 of the fourth cycle of first-line', 'platinum-based chemotherapy.', 'On study disease assessments, for the purposes of efficacy assessments will be performed', 'by a Central Radiographic Assessment Committee (CRAC) blinded to study treatment', 'information and independent of Investigators and personnel who are involved in', 'conducting the study (Section 5.3.1.1).', '5.2', 'Selection of Study Population', 'Current standard of care after first-line platinum-based chemotherapy consists primarily', 'of observation until disease progression, at which time second line chemotherapy, such as', 'with topotecan, may be instituted. No therapy is approved for use or routinely used as', 'maintenance or consolidation after first-line platinum-based chemotherapy in extensive', 'stage SCLC. Rovalpituzumab tesirine may be beneficial in this setting, but no prior', 'studies have formally explored its potential. Therefore, this study will involve a', 'comparison of rovalpituzumab tesirine against placebo.', '33']\n\n###\n\n", "completion": "END"}